Trial reportPloS one2026
The impact of short-term reduction in hepatic triglycerides on vascular health in adults with or at risk of metabolic dysfunction-associated steatotic liver disease.
Trial report in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05216796 (Diet Intervention to Promote Liver and Brain Health in Adults With Non-alcoholic Fatty Liver Disease), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Diet Intervention to Promote Liver and Brain Health in Adults With Non-alcoholic Fatty Liver Disease
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) increases cardiovascular risk, but the vascular benefits of reducing hepatic triglycerides remain unclear.
aimTo determine whether short-term diet-induced reductions in hepatic triglycerides improve arterial stiffness and endothelial function.
methodsIn a two-week, two-arm pre-post dietary intervention trial, adults with MASLD or elevated risk were assigned to either a low-carbohydrate (<30 g carbohydrate/day, n = 24) or low-calorie diet (~1,200-1,500 kcal/day, n = 23). Hepatic triglyceride content was assessed using proton density fat fraction magnetic resonance imaging. Vascular assessments included arterial stiffness as assessed by pulse wave velocity (PWV), and endothelial function via brachial artery flow-mediated dilation (FMD). The Framingham Risk Score (FRS) was evaluated pre- and post-intervention.
resultsAt baseline, 31 of 47 participants had MASLD. In the total sample, hepatic triglyceride content decreased by 15% relative to baseline (p < 0.001), with no significant differences between the two diet groups. Brachial-ankle PWV decreased by 41 cm/s (p = 0.001). FRS decreased (p < 0.001) and FMD (p = 0.030) increased by ~1.0% in absolute terms. Reductions in hepatic triglyceride content were positively correlated with changes in heart rate at rest (r = 0.49, p = 0.001), even after the adjustment of age and body weight change (r = 0.35, p = 0.021).
conclusionsVascular function improvements and cardiovascular risk reductions occurred along with hepatic triglyceride reduction following a two-week dietary intervention. Changes in hepatic triglyceride content were positively correlated with the corresponding changes in heart rate but not with measures of vascular function. (ClinicalTrials.gov, NCT05216796).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.